Ethics of a partially effective dengue vaccine: Lessons from the Philippines

Dengvaxia, a chimeric yellow fever tetravalent dengue vaccine developed by SanofiPasteur is widely licensed in dengue-endemic countries. In a large cohort study Dengvaxia was found to partially protect children who had prior dengue virus (DENV) infections but sensitized seronegative children to brea...

Descripción completa

Detalles Bibliográficos
Autores principales: Halstead, Scott B., Katzelnick, Leah C., Russell, Philip K., Markoff, Lewis, Aguiar, Maira, Dans, Leonila R., Dans, Antonio L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347470/
https://www.ncbi.nlm.nih.gov/pubmed/32654899
http://dx.doi.org/10.1016/j.vaccine.2020.06.079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347470/
https://www.ncbi.nlm.nih.gov/pubmed/32654899
http://dx.doi.org/10.1016/j.vaccine.2020.06.079

Ejemplares similares